Morphotek Obtains Exclusive License from Micromet for Antibody to Treat Melanoma and Other Cancers
14-Feb-2007 -
Micromet, Inc. and Morphotek(R) Inc. announced that Morphotek exercised its option under a 2004 agreement to obtain an exclusive worldwide license for an antibody targeting an antigen with potential activity for the treatment of certain cancers, including melanoma.
Under the terms of the ...
clinical trials
melanoma
Micromet
+1